Compare UTHR & ES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTHR | ES |
|---|---|---|
| Founded | 1996 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1B | 25.1B |
| IPO Year | 1999 | 1994 |
| Metric | UTHR | ES |
|---|---|---|
| Price | $571.09 | $71.28 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 11 |
| Target Price | ★ $567.57 | $71.00 |
| AVG Volume (30 Days) | 387.7K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.58% |
| EPS Growth | 13.07 | ★ 100.88 |
| EPS | ★ 27.86 | 4.56 |
| Revenue | $1,483,300,000.00 | ★ $13,547,244,000.00 |
| Revenue This Year | $6.39 | N/A |
| Revenue Next Year | $14.18 | $3.77 |
| P/E Ratio | $20.56 | ★ $15.58 |
| Revenue Growth | 2.38 | ★ 13.83 |
| 52 Week Low | $272.18 | $58.50 |
| 52 Week High | $607.89 | $76.41 |
| Indicator | UTHR | ES |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 60.35 |
| Support Level | $560.16 | $70.74 |
| Resistance Level | $593.65 | $71.40 |
| Average True Range (ATR) | 12.17 | 1.30 |
| MACD | -2.95 | 0.35 |
| Stochastic Oscillator | 33.53 | 87.37 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric, gas, and water distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. It plans to sell Aquarion in 2026. The company exited most of its unregulated businesses in 2006.